NCT07163728View on ClinicalTrials.gov

Leptin: A Marker for AML Chemo-Sensitivity

RecruitingOBSERVATIONAL
Enrollment

86

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
AMLAdult
Trial Locations (1)

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Medical University Union Hospital

OTHER

NCT07163728 - Leptin: A Marker for AML Chemo-Sensitivity | Biotech Hunter | Biotech Hunter